RBC Capital Defends Legend (LEGN) For Second Day in a Row As Stock Continues to Push Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to RBC Capital Defends Legend (LEGN) For Second Day in a Row As Stock Continues to Push Lower
December 8, 2025 9:08 AM EST
UBS analyst Ashwani Verma lowered the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $48.00 (from $54.00) while maintaining a Buy rating.... More
December 8, 2025 7:49 AM EST
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $74.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst commented: "With Latest Data Cuts, We Still Think Carvykti Looks To Have Superior Efficacy; Following updates at ASH this weekend, we... More
December 8, 2025 2:54 AM EST
Legend Biotech Corporation (NASDAQ: LEGN) announced clinical data showing a median progression-free survival of 50.4 months for triple-class exposed multiple myeloma patients who received three prior lines of therapy and were treated with CARVYKTI® (ciltacabtagene autoleucel) in the CARTITUDE-1 and CARTITUDE-4 studies.
The data was presented at the 67th American Society of Hematology Annual... More
